Medication info
Valsartan and Rosuvastatin Tablets 10/80 mg

Valsartan and Rosuvastatin Tablets 10/80 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletValsartan›80mg / 1 tablet
Manufacturer / importer
Myungmoon Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
30 tablets per box [(10 tablets/PTP) * 3]
Approval status
Active

MFDS item code 202003853 · Approved 2020.05.26 · Insurance code 649807670

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This drug should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose of valsartan is 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily. Thereafter, over several weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or higher. However, this drug should not be administered to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia; type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and should continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 3. Reduction in the risk of death after myocardial infarction 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Myungmoon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
View approved original text

This medication is used for patients who need to take both valsartan and rosuvastatin. Valsartan is effective for essential hypertension and heart failure, and it reduces the risk of mortality after myocardial infarction. It is particularly helpful for heart failure patients who are intolerant to ACE inhibitors. Rosuvastatin is used for the treatment of primary and familial hypercholesterolemia, mixed dyslipidemia, and it contributes to reducing the risk of cardiovascular diseases. Additionally, it controls hypercholesterolemia and delays the progression of atherosclerosis. The combination of these two medications can effectively improve cardiovascular health.

How to take

Adult dose

This drug should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose of valsartan is 80 mg orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is required, the dose may be increased to a maximum of 320 mg once daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this drug once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this drug once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this drug once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this drug once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this drug orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is coadministered, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this drug twice daily. Thereafter, over several weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Dose reduction should be considered if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dosage adjustment is required when creatinine clearance is 10 mL/min or higher. However, this drug should not be administered to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia; type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug, and should continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20mg of this drug to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this drug is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

1. Essential hypertension 6) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 3. Reduction in the risk of death after myocardial infarction 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication may cause serious harm to the fetus, especially after the second trimester, so it should be discontinued immediately upon confirmation of pregnancy. Women of childbearing potential should use appropriate contraceptive methods, and it is safe for pregnant or breastfeeding women to avoid this medication. This medication should not be administered to patients with severe liver or kidney dysfunction, liver cirrhosis, bile duct obstruction, or certain muscular diseases. Caution is needed for the elderly, patients with hyperkalemia, and those with liver disorders, and regular liver and kidney function tests are recommended. Because this medication lowers blood pressure, symptoms of hypotension or dizziness may occur, so caution should be exercised during driving or operating machinery. Additionally, if symptoms such as muscle pain or weakness occur, consulting a doctor immediately is necessary, and in severe cases, discontinuation of the medication may be needed. This medication may interact with other antihypertensive agents, diuretics, potassium supplements, and certain antibiotics, so it is essential to inform your doctor of any other medications being taken. In cases of overdose, severe hypotension or altered consciousness may occur, and immediate medical attention is required; blood dialysis is not effective. This medication has not been established for safety and efficacy in children and adolescents, so it should not be used. When storing, keep it out of reach of children and do not transfer it to other containers.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased blood levels of liver aminotransferases, increased blood creatinine phosphokinase, increased blood potassium, elevated gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes, diabetic complications, leg fracture, vertebral fracture, fracture, skin mass, second-degree AV block, vestibular neuritis, retinal detachment, unspecified skin neoplasm-like condition, herpes zoster, intervertebral disc herniation, laceration, hemoptysis, sputum disease, bronchitis, sensory disturbances, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, worsening hypertension, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reactions, palpitations, exacerbation of angina, auditory disturbances, hyperactive bladder, increased serum creatinine, prostatic hyperplasia, polyneuropathy, memory loss, peripheral neuropathy, cough, shortness of breath, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, amnesia, dissociative amnesia, memory disorders, confusion, hypotension, altered consciousness, circulatory collapse, shock, tachycardia, bradycardia, orthostatic dizziness, orthostatic hypotension, kidney function impairment, hyperkalemia, angioedema, reduced urine output, progressive azotemia, acute renal failure, vascular edema, erythema, pruritus, serum sickness, vasculitis, syncope, epistaxis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, edema, weakness, insomnia, erythema, decreased libido, dizziness, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal cramping, pharyngitis, arthralgia, drowsiness, atrial fibrillation, thirst, anorexia, malaise, vasculitis, hepatitis, arrhythmia, intestinal vascular edema, interstitial pneumonia, hypoglycemia, vascular edema, hepatitis, renal failure, shock, syncope, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, increased serum creatinine, elevated serum potassium, increased gamma-glutamyl transferase, myalgia, myopathy, rhabdomyolysis, transaminase elevation, pruritus, rash, urticaria, weakness, polyneuropathy, memory loss, peripheral neuropathy, cough, shortness of breath, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, amnesia, dissociative amnesia, memory disorders, confusion, severe muscle weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in light-resistant containers. Additionally, it should be stored at room temperature between 1 to 30 degrees Celsius, avoiding excessively hot or cold places.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

30 tablets per box [(10 tablets/PTP) * 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.